2017 Fiscal Year Final Research Report
Development of new radioisotope-labeled peptides for effective delivery in cancer therapy
| Project/Area Number |
15K19810
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Health Sciences University of Hokkaido |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 放射性医薬品 / octreotide / 腎臓 / がん / 体内動態 / インジウム-111 / アイソトープ内用療法 |
|---|
| Outline of Final Research Achievements |
Recently, Radioisotope (RI)-labeled peptides have been studied as therapeutic agents for cancer treatment. However, their clinical applications are difficult because of non-specific long-lasting accumulation of radioactivity in the kidney. To resolve this problem, we demonstrated the renal accumulation could be reduced by introducing a negative charge to peptide moiety with acidic amino acid. In addition, we also found that the elongation of amino acids to original peptide sequences dramatically increased tumor accumulation of radioactivity. In this study, we successfully developed a new RI-labeled peptide derivative which showed both lower renal radioactivity and higher tumor radioactivity by chemical modifications of the peptide sequence.
|
| Free Research Field |
放射性医薬品
|
